Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.

April 04, 2025

Vol.51 No.13

Drugs & Targets

CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer

BeiGene Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer.

April 04, 2025

Vol.51 No.13

In Brief

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.

March 28, 2025

Vol.51 No.12

In Brief

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named John Turchi, the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:

March 28, 2025

Vol.51 No.12

Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer

Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

YOU MAY BE INTERESTED IN

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

Renew today!

Subscriber content

Never miss an issue!

Login